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Objective:Many factors impair healing of chronic venous ulcer (CVU), and many theories have been proposed to explain
their pathogenesis. Coagulation factor XIII (FXIII) influences tissue regeneration and angiogenesis with effects on
wound healing. Because FXIII properties depend upon its genetic variants, we investigated whether intragene polymor-
phisms may have modulating effects on the CVU area.
Methods:The study included 121 patients with nonhealing CVUs (CEAP clinical class C6) that included 67%with primary
chronic venous disease (CVD), 26% with post-thrombotic ulcers, and 7% with mixed ulcer origin. Polymerase chain
reaction was used to genotype them for Val34Leu, Pro564Leu, and Tyr204Phe variants in the FXIII-A subunit gene and
forHis95Arg variant in the FXIII-B subunit gene. The same variants were analyzed in 102 controls, healthy subjects who
were case-matched by age and gender.
Results: Genotype distribution for all polymorphisms investigated was not significantly different between cases and
controls. Conversely, our CVU cases had a mean ulcer area inversely related with the presence of both Leu34 and Leu564
alleles (ValVal, 12.3 22.4 cm2 vs LeuLeu, 3.9 2.6 cm2, P .002; ProPro, 10.2 21.2 cm2 vs LeuLeu, 2.9 1.4 cm2,
P  .002). In combined analysis, those cases who were wild-type for both variants (ValVal34/ProPro564) had a further
increase inmean ulcer size compared with cases carrying both variants (Leu34/Leu564) (13.3 27.1 cm2 vs 5.2 5.6 cm2;
P  .034).
Conclusions: No correlation exists between FXIII genotypes and the prevalence of chronic venous ulcers, thus demon-
strating that FXIII polymorphisms have no role in ulcer development. In contrast, FXIII-gene variants, in particular the
non-wild-type alleles Leu34 and Leu564, were associated with a smaller venous ulcer surface and might have favorable
effects on reparative processes. ( J Vasc Surg 2006;44:815-9.)Venous ulcers are a severe clinical manifestation of
chronic venous insufficiency (CVI), which is responsible for
about 70% of chronic venous leg ulcers (CVUs).1 Several
other causes should be taken into account for CVU patho-
genesis, such as diabetes mellitus, rheumatoid arthritis,
trauma, sickle cell disease, vasculitis and skin tumor. In
Europe and in the United States, the prevalence of venous
ulcers is about 1%, with an estimated cost of $1 billion
yearly in the United States alone. In the United Kingdom,
14% of the health costs are devoted to wound care. The
prevalence varies greatly in function of sex, age, ethnicity,
environmental, and genetic factors. CVU prevalence is
approximately 0.3% in developed countries (1:350 adults)
and recurrence ranges from 54% to 78%.
About 3% to 5% of patients do not have an identified
cause of ulceration because it is often of multifactorial
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doi:10.1016/j.jvs.2006.06.006origin that may also involve genetic predispositions.2 In
addition, patients with nonhealing ulcers that are refractory
or resistant to conventional therapies do not have a suitable
therapy based on pharmacogenetic concepts that takes
genotype into account.
The biologic basis of tissue repair and remodelling after
wounding involves a complex interplay of factors where an
altered balance between proteolytic enzymes and their in-
hibitors has a crucial role.3 In addition, proteins of the
fibrinolytic system also play a role in wound healing by
regulating extracellular matrix (ECM) turnover. An im-
paired fibrinolytic activity, peculiar in chronic wounds, is
often associated with longstanding lesions. During the
early steps of healing, FXIII-crosslinked fibrin acts as a
provisional matrix at the wound site.4 A process of impaired
wound healing was described in CVU patients with FXIII
deficiency, and topical application of commercial FXIII was
reported to be an effective treatment.5-7
FXIII reduces the fibrinolytic activity at the wound site
by incorporation of 2-antiplasmin. In addition, the latter
effect blocks the fibrinolytic pathway of matrix metallopro-
teinase (MMP) activation by contrasting the uPA-plasmin
complex.8,9 Moreover, several authors reported a positive
role of FXIII in the healing process of different kinds of
lesions, such as those in chronic inflammatory bowel dis-
ease, cardiac rupture, and the diabetic foot.10-12
We recently showed increased regenerative capacities
in FXIII-treated fibroblasts in an in vitro system and
inversely significant associations between ulcer dimension
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highly polymorphic. Three common coding polymor-
phisms in its A-subunit gene have been described in Cau-
casian populations, potentially influencing FXIII proper-
ties.15 In the present study, we investigated if these
intragenetic polymorphisms, together with the FXIII-B
variant, might have significant effects on both ulcer estab-
lishment risk and in modulating reparative processes.
METHODS
Selection of patients. We enrolled 121 patients af-
fected by nonhealing CVU (CEAP clinical class C6) and
admitted to our Center of Vascular Diseases from 2002 to
2005. This group consisted of 30 patients added to an
existing study population of 91 patients from which we
previously reported the observation that the area of venous
ulceration was inversely proportional to the presence of
FXIII-A Val34Leu variant.14 Patients were selected from a
whole cohort of 258 cases of CVU, with the exclusion of
those who were not clearly referred to secondary or primary
CVD and with the exclusion of any other comorbidity
factor potentially affecting the healing process outcome,
including diabetes, peripheral arterial disease, or ankle-
brachial index 0.9; cardiac or hepatic or renal diseases,
leukemia, and autoimmune diseases.
Biopsy specimens were required in two patients. In the
first, result of the histology evaluation of the specimen was
negative, and the patient was included in the study. The
second patient was excluded because the examination re-
vealed a basocellular carcinoma.
Among selected patients, duplex scan investigations
demonstrated 67% with primary chronic venous insuffi-
ciency (CVI), 26%with post-thrombotic syndrome, and 7%
with mixed or congenital vascular origin, but with a pre-
dominantly venous component. All ulcer surfaces were
measured by means of Visitrak (Smith & Nephew, Ltd,
Worcs, UK). The cases consisted of 83 women and 38 men
with a mean age of 67  15 years. These consecutive
patients were affected by nonhealing ulcers with an estimated
course determined from clinical history of 3 months to 20
years, thus there was huge variability among the cohort.
Most patients were incorrectly treated by the referring
physicians with simple disinfection and dressing changes. A
few patients had infection at the time of our evaluation, but
no useful data were available about previous episodes. The
control group consisted of 102 healthy subjects without
any history of vascular disease who were recruited from the
blood donor file of the Ferrara Hospital. They were
matched by age and gender with the CVU cases. All sub-
jects enrolled in the study gave informed consent, and the
University-Hospital of Ferrara Ethics Committee approved
the study.
Determination of FXIII-A and FXIII-B subunit
genotypes. Genomic DNA was isolated from peripheral
blood by using standard proteinase-K treatment, followed
by phenol-chloroform extraction and ethanol precipitation.
Samples were genotyped by polymerase chain reaction by
means of PCR Rotor-Gene3000 (Corbett-Research Aus-tralia, Mortlake, NSW) for the Val34Leu, Pro564Leu, and
Tyr204Phe polymorphisms in the FXIII-A subunit gene
and His95Arg in the FXIII-B subunit gene according to
previously described methods.14-16 The different FXIII-
genotypes are indicated as normal homozygotes (wild-type),
heterozygote, and mutant homozygotes, respectively, for
ValVal, ValLeu, and LeuLeu. The same procedure was
done in a similar fashion for each of the other polymor-
phisms investigated.
Statistical analysis. Statistical differences between
cases and controls were performed by using the 2 test for
genotype distribution and Student’s t test for ulcer area.
The Yates correction or Fisher’s exact test was applied when
necessary. Logistic regression models, which account for
confounding variables such as sex, age, and other geno-
types were used to estimate the possible associations be-
tween gene variants and clinical or biologic phenotypes.
P  .05 was considered statistically significant.
RESULTS
The main characteristics of the populations investi-
gated are reported in Table I. Table II summarizes the
genotype distribution of the FXIII polymorphisms that was
investigated in the whole cohort of cases with the logistic
regression model. No differences statistically significant
were found between cases and controls in genotype fre-
quencies for all polymorphisms studied, thus excluding any
risk role ascribable to these FXIII gene variants in our
investigated population.
Table III summarizes the mean ulcer area distribution
stratified by FXIII different genotypes. The mean ulcer
surface in the whole cohort of patients was 10.6 19.7 cm2
(range, 1 to 150 cm2). Concerning the Val34Leu polymor-
phism, significant results were obtained for both compari-
sons (LeuLeu vs ValVal; P  .002 and ValLeu vs ValVal;
P  .016). For the Pro564Leu polymorphism, a significant
result was obtained only for LeuLeu homozygotes vs wild-
type individuals (LeuLeu vs ProPro; P .002). Concerning
the His95Arg substitution, owing to the presence of only
one ArgArg95 case, heterozygotes and homozygotes were
computed together vs wild-types (8.8  17.8 cm2 vs
Table I. Main characteristics of patients with chronic
venous ulcers and healthy controls
Characteristics
CVU
n  121
Controls
n  102
Age, years (mean  SD) 67  15 67  15
Range 27-85 27-85
Sex (male/female) 38/83 38/83
Ulcer etiology
Primary 81 (67%) —
Post-thrombotic 32 (26%) —
Mixed* 8 (7%) —
CVU, Chronic venous ulcers.
*Vascular and/or congenital origin.15.6  14.1 cm2, P  .07).
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pared those cases with double wild-type for both variants
(ValVal34/ProPro564),we observed a further increasing in
the ulcer area when compared with those carrying both
substitutions (Leu34/Leu564) (13.3  27.1 cm2 vs 5.2 
5.6 cm2; P  .034).
By subsetting primary from secondary CVU, the suba-
nalysis in primary cases confirmed the protective role of
Leu34 and Leu564 polymorphisms we found in the whole
group, whereas in the post-thrombotic cases it did not.
However, the relatively low number of primary and post-
thrombotic cases recruited could potentially be partly re-
sponsible for the presence/absence of the associations
found in our subanalyses.
No statistically significant correlation with ulcer area
was found for the Tyr204Phe polymorphism because this
polymorphism was very rare in the population of cases
investigated. Only 1 heterozygous individual and no ho-
mozygous individuals were found.
DISCUSSION
The exact mechanism underlying venous ulcer forma-
tion is poorly understood, and great effort from researchers
and clinicians has been expended toward understanding the
mechanisms controlling normal wound healing. The com-
plex cascade of wound healing involves inflammation, cell
proliferation and migration, ECM stabilization, remodel-
ling, angiogenesis, and apoptosis.
Several authors have previously demonstrated the role
of clinical variants that affect or delay the wound healing
process. Among these, high patient age and ulcer chronic-
ity, slow healing time, and surgically untreated superficial
venous reflux have been recognized as independent risk
Table II. Prevalence of factor XIII genotypes in patients
and controls
FXIII Genotype
CVU
n  121 (%)
Controls
n  102 (%)
Codon 34 (FXIII-A)
Val/Val 69 (57) 62 (61)
Val/Leu 44 (36) 32 (31)
Leu/Leu 8 (7) 8 (8)
Codon 564 (FXIII-A)
Pro/Pro 76 (63) 62 (61)
Pro/Leu 38 (31) 37 (36)
Leu/Leu 7 (6) 3 (3)
Codon 204 (FXIII-A)
Tyr/Tyr 120 (99) 97 (95)
Tyr/Phe 1 (1) 5 (5)
Phe/Phe — —
Codon 95 (FXIII-B)
His/His 108 (89) 89 (87)
His/Arg 12 (10) 13 (13)
Arg/Arg 1 (1) —
FXIII, Factor XIII; CVU, chronic venous ulcer.
No statistically significant differences were found in any of the comparisons
investigated for the FXIII gene variants.factors for healing and recurrence, as well as larger woundarea, duration of the wound, and fibrin on more than 50%
of lesion surface.17
To date, the molecular mechanisms have been poorly
investigated. To the best of our knowledge, no studies have
directly compared clinical variables with the ulcer size. In
particular, ambulatory venous pressure, the gold standard
of venous investigations, is not capable of categorizing
patients by clinical severity of the disease, and several over-
laps exist in ulcer appearance and among healthy and dis-
eased people. Successful wound healing rate and ulcer age
are correlated. In contrast, there is no demonstration in the
literature comparing ulcer age with ulcer size. Usually,
nonhealing ulcers have no tendency to heal—but also no
tendency to progress—and remain in a stall situation. For
these reasons, ourmolecular correlation with genotypemay
offer the opportunity to predict ulcer size in clinical prac-
tice.
The precise role of FXIII in the sequence of events in
these processes has not been well clarified to date. It seems
that its pleiotropic functions are ascribable in part to its
transglutaminase and proangiogenic activity.4 Several re-
ports described the involvement of FXIII in wound healing
of CVU, because it can be inferred from a delay in wound
repair that occurs in FXIII-deficient patients.5 Randomized
clinical trials and case reports have described positive effects
of FXIII concentrate in CVU healing.6,7
A FXIII-A gene polymorphism (Val34Leu) initially
described as protective against thrombosis increases the
molecule activity and modifies its crosslinking proper-
ties.18-20 The report describing the influence of two other
FXIII polymorphisms (Pro564Leu and Tyr204Phe) on the
activity of the molecule,21,22 led us to investigate their
possible role in CVU. FXIII-B His95Arg was recently de-
scribed having a role in increasing the dissociation rate of
the FXIII molecule, a necessary step for its full activation.23
The main finding of our study is the association be-
tween FXIII gene variants with ulcer size in CVU patients.
Concerning genotype distribution, the lack of significant
differences between our patients and controls may mean
that the FXIII gene variants do not have a role in the
establishment of CVU and that other inherited and or
environmental causative factors may be responsible for the
pathogenesis. On the other hand, ulcer area was inversely
related with the presence of the Leu34 or Leu564 allele in
an independent fashion and without synergistic effects. The
positive association between the Leu34 and Leu 564 alleles
and small ulcer dimension suggests that FXIII gene variants
can be considered “modulator factors” in lesion progres-
sion and extension, contributing in turn to increased fibrin
matrix stability.
The significant protective effect demonstrated in the
whole group of venous ulcers was not confirmed for pa-
tients affected by post-thrombotic ulcers when we per-
formed a subanalysis of primary and post-thrombotic cases.
In contrast, the significance was even stronger in primary
cases. The reason for a lack of significance in the post-
thrombotic group could be related to several factors:
otes i
JOURNAL OF VASCULAR SURGERY
October 2006818 Tognazzo et al1. The more severe hemodynamic impairment of post-
thrombotic limbs could minimize the protective mech-
anisms found in primary cases, which will be discussed
further; and
2. Wild-type FXIII is more likely to be found in the post-
thrombotic group because this genetic variant, as al-
ready discussed, is associated with an increased risk of
venous thrombosis and thus affects the genotype distri-
bution in post-thrombotic cases.
Our findings suggest that the coagulation FXIII gene
variants can be considered “modulator factors” in lesion
progression and extension, suggesting positive role in tissue
repair together with other known and unknown inherited
and acquired situations. The Leu34 variant confers a mole-
cule with higher FXIII activity and increases the incorpo-
ration rate of fibrinolysis inhibitors in fibrin provisional
matrix. This latter property could effectively contrast the in
vivo plasmin-dependent activation of pro-MMP by direct
plasmin-antiplasmin inhibition. This could prevent hyper-
fibrinolysis at the wound site, where an earlier-activated
FXIII molecule basically becomes more available to cross-
link ECM components, stabilizing them against wasteful
proteolysis.8 This condition could improve in vivo prolifer-
ation and migration of fibroblast cells, favoring in turn
ECM protein deposition.24,25 In the same way, the re-
ported FXIII-dependent increased phagocyte activity of
macrophages could become higher in presence of
FXIII34Leu molecule, a fact that could be useful for skin
ulceration treatment.26,27
The Leu564 polymorphism lies near the active site
residue (Tyr-560) of the FXIII molecule. The replacement
of proline with a leucine was described as potentially affect-
ing FXIII activity and, in turn, improving specific substrate
binding.22,28 Thus, the properties of Leu564 could in part
explain the modulator effect on lesion extension. Investi-
gations on the structure-function relationships of
Pro564Leu are warranted. The number of individuals car-
rying the PhePhe204 genotype in the FXIII-A or the Ar-
gArg 95 genotype in the FXIII-B was too low to draw
definite conclusions. From this point of view, a limitation of
the prognostic role of FXIII found in the present study is
the lack of a statistical analysis of power. We did not
perform that analysis because it required a larger number
Table III. The mean ulcer areas stratified by factor XIII p
Cases
N 121
FXIII-A
Val34Leu
FX
Pro5
Wild-types (69) 12.3  22.4 (76) 10
Heterozygotes (44) 6.0  6.7 (38) 9
Homozygotes (8) 3.9  2.6 (7) 2
P* .002 .0
FXIII, Factor XIII.
Values are the means (cm2  SD) of the ulcer areas. In parenthesis are the
*Refers to the comparison between homozygous vs wild-type. Homozyg
cases† were computed together.of homozygotes than we had in our survey. It wouldcertainly be interesting to assess this in a large multi-
center study.
CONCLUSION
Because the main aims in ulcer treatment are healing
and avoiding recurrences, the precise identification of risk
and prognostic and modulators factors significantly related
to CVU establishment and progression should allow a
better tailored treatment, particularly for those patients
who are unresponsive to standard care, and also predict
clinical outcome. Because we found no correlations be-
tween FXIII-genotype and chronic venous ulcers establish-
ment and that particular FXIII-gene variants (ie, Leu34
and Leu564) were associated with smaller ulcer areas, we
intend to investigate whether topical application of a re-
combinant FXIII containing such variants might have fa-
vorable effects in nonhealing venous ulcers.
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